669
Participants
Start Date
May 20, 2021
Primary Completion Date
November 15, 2024
Study Completion Date
August 1, 2025
mRNA-1273 SARS-CoV-2 vaccine
Contains 1.26 mg of CX-024414 mRNA and 24.38 mg of SM-102 LNP as a white to off-white dispersion in preservative-free diluent buffer at pH 7.5.
BNT162b2
A white to off-white, sterile, preservative-free, frozen suspension for intramuscular injection, supplied with 0.9% sodium chloride diluent for injection plastic ampoules.
ChAdOx1-S [recombinant]
A colourless to slightly brown, clear to slightly opaque solution containing 5 x 1010 viral particles (not less than 2.5 x 108 infectious units).
0, 28 day schedule
Second injection administered 28 days post first injection
0, 112 day schedule
Second injection administered 112 days post first injection
Covifenz
COVIFENZ is an emulsion for intramuscular injection. The 3.75 mcg antigen component of COVIFENZ is a suspension, which must be mixed 1:1 with the 0.25 mL AS03 adjuvant emulsion component prior to administration
Royal Inland Hospital, Kamloops
Penticton Regional Hospital, Penticton
Children's Hospital Research Institute of Manitoba, Winnipeg
Canadian Center for Vaccinology, Halifax
Ottawa Hospital Research Institute, University of Ottawa, Ottawa
CHU de Québec, Université Laval, Québec
BC Children's Hospital Research Institute, Vancouver
McGill University Health Centre Vaccine Study Centre, Montreal
Collaborators (2)
Canadian Center for Vaccinology
OTHER
BC Children's Hospital Research Institute
OTHER
Children's Hospital Research Institute of Manitoba
OTHER
CHU de Quebec-Universite Laval
OTHER
Ottawa Hospital Research Institute
OTHER
Ontario Agency for Health Protection and Promotion
OTHER_GOV
University of Toronto
OTHER
Massachusetts General Hospital
OTHER
Interior Health
INDUSTRY
McGill University Health Centre/Research Institute of the McGill University Health Centre
OTHER
Canadian Immunization Research Network
NETWORK